Regeneron Pharmaceuticals

REGN · NASDAQ · USD

$735.20+0.05%+$0.39

Close · October 2, 2026

At a glance

Revenue growth: +0.99%; 2025 vs 2024
Net income growth: +2.09%; 2025 vs 2024
Net margin: 31.4%; 2024: 31.1%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	4,291	3,605	3,884	3,754	3,676	3,029	3,789	3,721	3,547	3,145	3,434	3,363
Cost of revenue	2,208	2,213	2,211	1,997	1,952	1,792	1,978	1,763	1,680	1,682	1,694	1,512
Gross profit	2,083	1,393	1,674	1,758	1,724	1,237	1,812	1,958	1,867	1,463	1,740	1,851
Selling, general and administrative	662	648	775	658	634	633	792	714	759	689	738	641
Research and development	1,632	1,544	1,626	1,475	1,432	—	—	—	—	—	—	—
Operating income	1,421	745	899	1,110	1,090	604	1,020	1,244	1,108	774	1,003	1,211
EBIT	1,421	745	899	1,110	1,090	604	1,020	1,244	1,108	774	1,003	1,211
EBITDA	1,544	868	1,044	1,247	1,225	731	1,146	1,365	1,229	888	1,116	1,316
Interest expense	11.0	12.9	12.2	19.3	3.6	8.7	10.5	13.8	14.8	16.1	18.3	17.8
Pre-tax income	1,528	831	1,044	1,763	1,519	905	958	1,493	1,628	701	1,148	1,111
Income tax	231	104	199	303	127	96.3	40.4	152	196	-21.3	-12.0	103
Net income	1,297	727	845	1,460	1,392	809	918	1,341	1,432	722	1,160	1,008
Net income to common shareholders	1,297	727	845	1,460	1,392	809	918	1,341	1,432	722	1,160	1,008
Basic EPS	12.62	6.99	8.21	14.09	13.24	7.58	8.53	12.40	13.25	6.70	10.88	9.48
Diluted EPS	12.23	6.75	7.86	13.62	12.81	7.27	8.07	11.54	12.41	6.27	10.19	8.89
Average shares (basic)	103	104	103	104	105	107	108	108	108	108	107	106
Average shares (diluted)	106	108	108	107	109	111	114	116	115	115	114	113
Dividend per share	0.94	0.94	0.88	0.88	0.88	0.88	—	—	—	—	—	—